Learning Hub
Explore resources to help you understand and manage psoriatic arthritis.
Search
Search this site
172 results found with an empty search
- iPROLEPSIS Newsletter No. 11 | iPROLEPSIS
< BACK iPROLEPSIS Newsletter No. 11 Mar 10, 2026 Latest News from iPROLEPSIS Welcome to the eleventh edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. iPROLEPSIS project newsletter Issue No. 11_March 2026 .pdf Download PDF • 4.21MB iPROLEPSIS_Newsletter 11.png iPROLEPSIS_Newsletter 11.png 1/1 PREVIOUS NEXT
- World Psoriasis Day 2025: Advancing Prevention and Care | iPROLEPSIS
< BACK World Psoriasis Day 2025: Advancing Prevention and Care Oct 29, 2025 On World Psoriasis Day, iPROLEPSIS highlights ongoing efforts to improve early detection, prevention, and digital support for people living with psoriasis and psoriatic arthritis October 29 marks World Psoriasis Day – a day dedicated to raising awareness of the impact psoriasis has on millions worldwide. For many, the condition goes beyond the skin: up to 30% develop psoriatic arthritis , an inflammatory disease that causes joint pain, stiffness, and fatigue, significantly affecting daily life. This year’s World Psoriasis Day video shares how iPROLEPSIS is working to advance psoriatic arthritis prevention and care. Through clinical studies, digital biomarkers, and co-created digital health tools, the project aims to support early detection , timely monitoring , and personalised care . The ongoing PDPID study is developing and validating predictive models for psoriatic arthritis progression, while the iPROLEPSIS digital ecosystem – including the miPROLEPSIS apps, miDashboard for professionals, and lifestyle interventions – is designed together with patients and clinicians to make technology more supportive of everyday care. Its tools – the miPROLEPSIS and miPROLEPSIS-Lite apps, the miDashboard for professionals, and lifestyle interventions such as serious games and personalised recommendations – are co-created with patients and healthcare providers to ensure they are practical, easy to use, and truly supportive of everyday care. On this World Psoriasis Day, iPROLEPSIS stands with everyone living with psoriasis and psoriatic arthritis. Together with clinical and research partners across Europe, the project continues to work toward earlier detection, prevention, and innovative digital solutions to improve lives. Watch the World Psoriasis Day 2025 video here: https://www.youtube.com/watch?v=FvbTCNH9vMY Screenshot 2025-10-29 083418.png Screenshot 2025-10-29 083418.png 1/1 PREVIOUS NEXT
- User Research and Co-Creation | iPROLEPSIS
< BACK User Research and Co-Creation Aug 4, 2023 User Research and Co-Creation are at the core of iPROLEPSIS research process Within iPROLEPSIS , several Digital Health Tools (DHTs) will be developed with the aim to early detect the transition to PsA in PsO patients, to predict flares to allow for early intervention, and to generate personalised recommendations and personalised interventions that help manage the disease. The different DHTs to be developed are: miPROLEPSIS patient app; miPROLEPSIS healthcare practitioner dashboard; biAURA biaural sounds app; Personalised recommendation system; Personalised Gaming Suite (PGS). At iPROLEPSIS , User Research and Co-Creation form the foundation of the research process. Diverse qualitative and quantitative research methods have been employed, including interviews, observations, surveys, and usability testing, to gather data and refine our healthcare solutions. One key approach has been conducting 10 focus groups with Dutch, English, Portuguese, and Greek Psoriatic Arthritis (PsA) patients . Four prominent themes emerged from the focus group discussions: Disease Activity, Coping, Care Experience, Digital Biomarkers. To obtain more specific input from a broader population of PsA patients, a survey was created. The survey consisted of 5 sections dedicated to the following: Demographics & Technological Experience ; miPROLEPSIS Patient App - Content and Appearance; BiAURA App – Preferences; Personalised Serious Gaming Suite – Content and Appearance. Key highlights of the insights gained include: Creation of a Patient Experience Map . Psoriatic Arthritis (PsA) has a great impact on the life of those affected. Emotional wellbeing is highly related to the experienced disease activity fluctuating over time. The patient experience map relates the level of disease activity over time to the level of emotional wellbeing in a graph. The graph was created to empathise with our end users and indicate where our Digital Health Solutions might be able to help with improving their Emotional Wellbeing during various stages of disease. Development of User Personas . Engaging and relatable descriptions of user needs and desires, guiding user-centered design principles for our digital products. User Requirement Updates. Refinement of User Requirements for the Digital Health Tools based on focus group findings, ensuring that our tools meet the real needs of PsA patients. iPROLEPSIS is committed to advancing Psoriatic Arthritis (PsA) management through cutting-edge technology and empathetic design. News & Events iPROLEPSIS - news.png News & Events iPROLEPSIS - news.png 1/1 PREVIOUS NEXT
- Federated AI for Privacy-Preserving Omics Profiling seminar | iPROLEPSIS
< BACK Federated AI for Privacy-Preserving Omics Profiling seminar Jun 18, 2024 Advancing Knowledge in Privacy-Preserving AI for Omics Profiling On 18 June 2024, iPROLEPSIS had the opportunity to attend an online seminar organised by our sister project, IMMEDIATE EU Project. The seminar's topic was Federated AI for Privacy-Preserving Omics Profiling, presented by Prof. Dr. Jan Baumbach. Prof. Baumbach is the chair of the Computational Systems Biology lab at the University of Hamburg and leads the Computational BioMedicine group at the University of Southern Denmark. A big thank you to Prof. Baumbach for sharing his expertise and insights on this cutting-edge topic! 1/14 PREVIOUS NEXT
- Ongoing preparation for the iPROLEPSIS-PDPID study | iPROLEPSIS
< BACK Ongoing preparation for the iPROLEPSIS-PDPID study Mar 4, 2024 iPROLEPSIS-PDPID Study: Advancing Psoriatic Arthritis through Innovative Digital Biomarkers Patients with Psoriatic arthritis (PsA) experience difficulties in dealing with unpredictable disease activity, which can affect their quality of life. Developing a digital biomarker using a smartphone and smartwatch would allow for unobtrusive monitoring of the disease activity in these patients. Besides, understanding what factors trigger flare would allow for better disease control. The iPROLEPSIS-PDPID study is a multicentre observational cohort study that aims to develop an unobtrusive and affordable digital biomarker capable of detecting changes in disease activity, including flare, and to identify triggers of flare in patients with PsA. The study will be conducted in four countries: the Netherlands, the UK, Portugal and Greece. Ethical approval for initiating the iPROLEPSIS-PDPID study in the Netherlands and the UK has been granted. The OpenClinica platform will be used in the collection and storage of data for the iPROLEPSIS-PDPID study. Future steps include obtaining ethical approvals for Portugal and Greece as well as local approvals from centres participating in each country, and inclusion of patients from each participating country. The miPROLEPSIS phone app , currently under development, will be used in this study. The app will be installed on the patient smartphone and utilised as a data collector, which will be then used for algorithms development and training. The app will measure physical activity, the length of sleep, self-registered flare, and register daily pain, fatigue, sleep and morning stiffness. The Garmin smartwatch Vivoactive 5 device will be used to collect data on physical activity, heart rate, heart rate variability and sleep quality. The collected data from Garmin will be downloaded from the miPROLEPSIS app by Wellics software (developer in the project), which allows extracting, visualising and exporting collected both company-processed data, as well as raw data. 10.png 13.png 14.png 10.png 1/5 PREVIOUS NEXT
- iPROLEPSIS Presented at Health Data Summit 2025 | iPROLEPSIS
< BACK iPROLEPSIS Presented at Health Data Summit 2025 Mar 27, 2025 Showcasing practical strategies for high-quality data mapping and harmonisation At Health Data Summit 2025 , organised by the European Institute for Innovation Through Health Data (i~HD) on March 18–19 in Brussels , the iPROLEPSIS project was presented by Thanos Vidakis from AINIGMA Technologies . The presentation was part of the session titled: "Advanced Strategies and Tools for Ensuring High-Quality Data During Data Mapping". It focused on how iPROLEPSIS uses the OMOP Common Data Model (CDM) and OHDSI tools to harmonize health datasets from various sources. By applying coding standards such as SNOMED , the project ensures consistency and interoperability across data systems. The talk also highlighted recent hands-on workshops with data experts , during which real-world data was mapped to the OMOP model and underwent quality checks . These steps are essential in delivering analytics-ready health data — a key goal of the project. iPROLEPSIS continues to support high standards in digital health research by promoting data quality, standardisation, and collaboration across partners. 1/2 PREVIOUS NEXT
- How will psoriatic arthritis affect me? Relationships and Family Planning | iPROLEPSIS
Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search How will psoriatic arthritis affect me? Relationships and Family Planning See related Handbook section PREVIOUS NEXT
- iPROLEPSIS Games Presented at Centro Neurológico de Torres Vedras | iPROLEPSIS
< BACK iPROLEPSIS Games Presented at Centro Neurológico de Torres Vedras Jul 21, 2026 The visit offered an opportunity to present the iPROLEPSIS Games and discuss the project’s work with the centre’s team On 8 July 2026, the Faculdade de Motricidade Humana from University of Lisbon team visited the Centro Neurológico de Torres Vedras in Portugal to present the iPROLEPSIS Games. The visit provided an opportunity to introduce the iPROLEPSIS games, share the team’s work and exchange insights with the centre’s staff. The iPROLEPSIS Games are being developed as part of the project’s work on digital tools for people with psoriatic arthritis. cns4.png cns2.jpeg cns1.jpeg cns4.png 1/3 PREVIOUS NEXT
- Seasons Greetings from iPROLEPSIS | iPROLEPSIS
< BACK Seasons Greetings from iPROLEPSIS Dec 23, 2025 Happy holidays and best wishes for the year ahead! We wish you a warm and peaceful holiday season. May the coming year bring good health, positive moments, and new opportunities. Happy holidays! iPROLEPSIS iPROLEPSIS Happy Holidays.png iPROLEPSIS Happy Holidays.png 1/1 PREVIOUS NEXT
- iPROLEPSIS Games Selected for HiTech 2025 | iPROLEPSIS
< BACK iPROLEPSIS Games Selected for HiTech 2025 Feb 13, 2025 Transforming Research into Real-World Solutions The iPROLEPSIS consortium partners from FMH/IST-ULisboa are pleased to announce that iPROLEPSIS Games has been selected as one of the 16 teams for the HiTech 2025 Program . HiTech 2025, organised by HiSeedTech , supports research teams in transforming deep tech innovations into market-ready solutions . This selection marks an exciting step forward for iPROLEPSIS Games , reinforcing our commitment to bridging the gap between scientific research and practical applications . 🔗 Read more about the program: HiSeedTech: Programs 1/1 PREVIOUS NEXT
- iPROLEPSIS Clinical Studies' Planning | iPROLEPSIS
< BACK iPROLEPSIS Clinical Studies' Planning Feb 13, 2023 iPROLEPSIS team starts the planning of the four clinical studies that will be conducted in the project. iPROLEPSIS team starts the planning of the four clinical studies that will be conducted in the project. iPROLEPSIS plans to carry out: 1) a study to design novel digital biomarkers for PsA; 2) a study to investigate new opto-acoustics biomarkers and the role of mast cells in PsA; 3) a study to validate the potential of the novel digital biomarkers to screen for PsA in persons with psoriasis; and 4) a study to evaluate the effectiveness of the envisioned iPROLEPSIS digital care ecosystem in reducing flares of persons with PsA. Office Scene .jpg Office Scene .jpg 1/1 PREVIOUS NEXT
- The iPROLEPSIS Learning Hub Has Been Renewed | iPROLEPSIS
< BACK The iPROLEPSIS Learning Hub Has Been Renewed Oct 14, 2025 A refreshed space to learn more about psoriatic arthritis The iPROLEPSIS Learning Hub has been renewed with a new design, structure, and additional content to make exploring its materials more intuitive and engaging. The updated platform offers accessible information and practical resources related to psoriatic arthritis , supporting users who wish to learn more about the condition and its management. Explore resources on psoriatic arthritis The renewed Learning Hub brings together several sections that guide visitors through different aspects of the condition: Psoriatic Arthritis Handbook – an overview of psoriatic arthritis, including symptoms, diagnosis, and management. Key Facts – short explanations and definitions to help understand key topics. Interactive Quizzes – quick checks to support learning in an engaging way. News Feed – a selection of updates and materials from external, recognised sources. A space to learn and stay informed The Learning Hub offers a simple way to explore information about psoriatic arthritis and to learn more about its characteristics, treatment approaches, and impact on daily life. Visit the renewed Learning Hub : https://www.iprolepsis.eu/learning-hub-new iPROLEPSIS_Learning Hub.png iPROLEPSIS_Learning Hub.png 1/1 PREVIOUS NEXT